Market News

Ally Financial Has Decreased Its Lowe’s Cos (LOW) Stake; Pacira Pharmaceuticals, Inc. (PCRX) Covered By 10 Bullish Analysts Last Week

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Logo

Among 22 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pacira Pharmaceuticals had 103 analyst reports since July 28, 2015 according to SRatingsIntel. Wedbush maintained the shares of PCRX in report on Wednesday, March 7 with “Buy” rating. The company was maintained on Thursday, January 4 by Wedbush. As per Wednesday, February 28, the company rating was maintained by Piper Jaffray. Wedbush maintained it with “Buy” rating and $87.0 target in Wednesday, October 25 report. The firm earned “Buy” rating on Friday, February 26 by Brean Capital. The firm earned “Buy” rating on Wednesday, August 2 by Mizuho. The company was maintained on Sunday, July 30 by RBC Capital Markets. The rating was initiated by H.C. Wainwright on Tuesday, January 3 with “Buy”. The rating was initiated by Nomura with “Buy” on Tuesday, September 29. Canaccord Genuity maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) rating on Monday, May 29. Canaccord Genuity has “Buy” rating and $6000 target. See Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) latest ratings:

10/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $40 New Target: $43 Maintain
09/04/2018 Broker: Mizuho Rating: Hold New Target: $31.0000 Maintain
09/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $48.0000 Maintain
09/04/2018 Broker: Piper Jaffray Rating: Buy New Target: $44.0000 Maintain
08/04/2018 Broker: Seaport Global Rating: Buy New Target: $48.0000 Maintain
05/04/2018 Broker: Wedbush Rating: Buy New Target: $72.0000 Maintain
09/04/2018 Broker: Canaccord Genuity Old Rating: Hold New Rating: Hold Old Target: $32 New Target: $34 Maintain
09/04/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $31 New Target: $34 Maintain
20/03/2018 Broker: Seaport Global Rating: Buy New Target: $42.0 Maintain
07/03/2018 Broker: Wedbush Rating: Buy New Target: $72.0 Maintain

Ally Financial Inc decreased Lowe’s Cos Inc (LOW) stake by 85% reported in 2017Q4 SEC filing. Ally Financial Inc sold 34,000 shares as Lowe’s Cos Inc (LOW)’s stock declined 5.74%. The Ally Financial Inc holds 6,000 shares with $558,000 value, down from 40,000 last quarter. Lowe’s Cos Inc now has $71.55 billion valuation. The stock increased 0.68% or $0.58 during the last trading session, reaching $86.64. About 1.48 million shares traded. Lowe's Companies, Inc. (NYSE:LOW) has risen 5.39% since April 17, 2017 and is uptrending. It has underperformed by 6.16% the S&P500.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.47 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

Investors sentiment increased to 1.4 in Q4 2017. Its up 0.01, from 1.39 in 2017Q3. It is positive, as 29 investors sold Pacira Pharmaceuticals, Inc. shares while 41 reduced holdings. 31 funds opened positions while 67 raised stakes. 40.06 million shares or 3.76% less from 41.63 million shares in 2017Q3 were reported. Tygh owns 0.78% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 91,161 shares. Venbio Select Advisor Llc reported 2.51% stake. Mirae Asset Global Invs Com holds 0.02% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 37,895 shares. Denver Investment Advsr Ltd Co holds 0.03% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 12,552 shares. Granahan Mgmt Ma holds 0.62% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 172,152 shares. Amalgamated Bancorporation has 0.01% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 5,340 shares. Voya Inv Mgmt Lc holds 588,447 shares or 0.06% of its portfolio. Moreover, Rock Springs Capital Mgmt Ltd Partnership has 2.29% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 1.11M shares. Goldman Sachs Gp Inc has 143,933 shares for 0% of their portfolio. State Street Corporation holds 986,585 shares or 0% of its portfolio. Oppenheimer Asset Mngmt holds 7,375 shares or 0.01% of its portfolio. Principal Financial Group invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Moreover, Oak Ridge Invests Lc has 0.63% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 288,887 shares. Pacad Investment invested in 0.04% or 4,300 shares. Moreover, Rice Hall James And Assocs Ltd Liability has 0.58% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 323,769 shares.

Since December 15, 2017, it had 0 insider purchases, and 2 selling transactions for $1.18 million activity. 340 shares were sold by Riker Lauren Bullaro, worth $14,858. 28,885 shares were sold by STACK DAVID M, worth $1.16 million on Wednesday, January 10.

The stock increased 0.84% or $0.3 during the last trading session, reaching $36.05. About 308,934 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has declined 33.05% since April 17, 2017 and is downtrending. It has underperformed by 44.60% the S&P500.

Analysts await Lowe's Companies, Inc. (NYSE:LOW) to report earnings on May, 23. They expect $1.29 EPS, up 25.24% or $0.26 from last year’s $1.03 per share. LOW’s profit will be $1.07 billion for 16.79 P/E if the $1.29 EPS becomes a reality. After $0.74 actual EPS reported by Lowe's Companies, Inc. for the previous quarter, Wall Street now forecasts 74.32% EPS growth.

Investors sentiment decreased to 1.01 in 2017 Q4. Its down 0.03, from 1.04 in 2017Q3. It dropped, as 48 investors sold LOW shares while 437 reduced holdings. 138 funds opened positions while 351 raised stakes. 585.84 million shares or 0.67% less from 589.78 million shares in 2017Q3 were reported. Great West Life Assurance Communication Can holds 0.41% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW) for 1.85 million shares. Moreover, Horizon Service Limited Liability has 2.07% invested in Lowe's Companies, Inc. (NYSE:LOW). Osborne Partners Cap Management Lc owns 115,140 shares. 125,500 are owned by Shelter Mutual Ins. Cornerstone Inc owns 47,000 shares or 0.5% of their US portfolio. Strategic Advsr Limited Com holds 4,505 shares. D E Shaw reported 1.90 million shares or 0.24% of all its holdings. Kentucky-based Stock Yards Bancorp & Tru has invested 0.11% in Lowe's Companies, Inc. (NYSE:LOW). Boston Private Wealth Ltd holds 17,318 shares or 0.06% of its portfolio. Korea Inv Corp reported 0.43% stake. 3,242 are held by Leisure Capital Mngmt. Gilman Hill Asset Mngmt Ltd owns 5,411 shares. First City Mgmt Inc reported 0.73% stake. 1.43 million are owned by Franklin Resource. Balasa Dinverno And Foltz Lc invested 0.06% in Lowe's Companies, Inc. (NYSE:LOW).

Among 35 analysts covering Lowe’s Companies Inc. (NYSE:LOW), 22 have Buy rating, 0 Sell and 13 Hold. Therefore 63% are positive. Lowe’s Companies Inc. had 97 analyst reports since August 19, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 23 by Stifel Nicolaus. The rating was initiated by Bernstein with “Underperform” on Monday, February 6. The firm has “Buy” rating given on Monday, February 5 by Jefferies. The rating was initiated by Topeka Capital Markets with “Hold” on Tuesday, May 24. The company was maintained on Wednesday, January 24 by Robert W. Baird. The rating was maintained by Longbow with “Buy” on Friday, August 14. The firm has “Buy” rating given on Wednesday, July 5 by RBC Capital Markets. SunTrust maintained the stock with “Hold” rating in Wednesday, November 22 report. The company was maintained on Thursday, November 19 by Argus Research. The rating was downgraded by Wedbush to “Neutral” on Wednesday, October 26.

Ally Financial Inc increased Merck & Co Inc (NYSE:MRK) stake by 108,949 shares to 178,000 valued at $10.02 million in 2017Q4. It also upped American International Group Inc (NYSE:AIG) stake by 13,000 shares and now owns 68,000 shares. Microsoft Corp (NASDAQ:MSFT) was raised too.

Lowe's Companies, Inc. (NYSE:LOW) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *